BMS unit Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have urged the US Supreme Court to reinstate their $1.2 billion win in a patent clash with Kite Pharma, a subsidiary of Gilead.
The Federal Court of Australia has refused an appeal request in a decade-long case brought by Boehringer Ingelheim Animal Health against MSD subsidiary, Intervet International.
The UK government will implement the Genetic Technology Bill which promises to “remove unnecessary barriers” inherited from the European Union to bolster gene-editing technology.
Canadian pharmaceutical company GlycoBioSciences has sued cosmetics giant L’Oreal, alleging that the French company’s anti-wrinkle products containing hyaluronic acid infringe two patents.
Moderna has rejected claims that its COVID-19 vaccine violates the patent rights of two biopharma companies, arguing that its contract with the US federal government has conferred immunity.
Harvard College and 10x Genomics have sued Nanostring Technologies, alleging that the company’s CosMx imaging platform infringes two patents covering “gene-mapping” technology.
Patents core to the breakthrough gene-editing technology CRISPR belong to the University of Harvard and the Massachusetts Institute of Technology’s Broad Institute, the US Patent and Trademark Office has ruled.
The US International Trade Commission will investigate whether drug manufacturers used trade secrets to develop a biosimilar of AbbVie’s Humira.
Alexion, AstraZeneca’s rare disease group, has entered into an exclusive licensing agreement with Neurimmune AG for NI006, an antibody in development for the treatment of the heart condition, transthyretin amyloid cardiomyopathy.
Biotech Allele has dropped its lawsuit accusing Pfizer and BioNTech of infringing technology covering a fluorescent protein used in COVID-19 vaccines.